Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Exercise | 24 | 2024 | 173 | 6.300 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2024 | 3 | 1.660 |
Why?
|
| Cytomegalovirus Infections | 5 | 2017 | 25 | 1.530 |
Why?
|
| Humans | 29 | 2025 | 4936 | 1.170 |
Why?
|
| T-Lymphocytes | 4 | 2020 | 46 | 1.120 |
Why?
|
| Adult | 18 | 2025 | 1567 | 1.120 |
Why?
|
| Physical Fitness | 3 | 2023 | 22 | 1.090 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2017 | 17 | 1.030 |
Why?
|
| Cytokines | 4 | 2020 | 37 | 1.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 9 | 2023 | 37 | 1.020 |
Why?
|
| Quality of Life | 2 | 2022 | 87 | 0.790 |
Why?
|
| Male | 17 | 2023 | 2491 | 0.780 |
Why?
|
| Killer Cells, Natural | 4 | 2023 | 32 | 0.770 |
Why?
|
| Monocytes | 3 | 2018 | 18 | 0.730 |
Why?
|
| Pancreatic Neoplasms | 1 | 2022 | 15 | 0.730 |
Why?
|
| Healthy Volunteers | 3 | 2018 | 37 | 0.710 |
Why?
|
| Saliva | 1 | 2020 | 19 | 0.660 |
Why?
|
| Sleep | 1 | 2020 | 62 | 0.630 |
Why?
|
| Lymphocyte Activation | 3 | 2018 | 15 | 0.620 |
Why?
|
| Exercise Therapy | 3 | 2024 | 24 | 0.590 |
Why?
|
| Reward | 1 | 2018 | 9 | 0.570 |
Why?
|
| Cytomegalovirus | 3 | 2017 | 12 | 0.570 |
Why?
|
| Female | 11 | 2025 | 2523 | 0.570 |
Why?
|
| Dendritic Cells | 2 | 2015 | 7 | 0.570 |
Why?
|
| Cell Differentiation | 2 | 2015 | 71 | 0.530 |
Why?
|
| Immune System | 3 | 2013 | 11 | 0.480 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2015 | 8 | 0.450 |
Why?
|
| Antigens, Neoplasm | 1 | 2015 | 8 | 0.450 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 17 | 0.440 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 3 | 0.420 |
Why?
|
| Coinfection | 1 | 2014 | 3 | 0.420 |
Why?
|
| Herpes Simplex | 1 | 2014 | 7 | 0.420 |
Why?
|
| Young Adult | 8 | 2025 | 787 | 0.420 |
Why?
|
| Immunity, Innate | 1 | 2013 | 8 | 0.410 |
Why?
|
| Flow Cytometry | 4 | 2018 | 39 | 0.370 |
Why?
|
| Biomarkers | 2 | 2023 | 81 | 0.360 |
Why?
|
| Cold Temperature | 1 | 2011 | 3 | 0.360 |
Why?
|
| Inflammation | 3 | 2023 | 57 | 0.360 |
Why?
|
| Hydrocortisone | 3 | 2020 | 18 | 0.350 |
Why?
|
| Obesity | 3 | 2021 | 115 | 0.320 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2023 | 13 | 0.300 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2020 | 40 | 0.300 |
Why?
|
| Inflammasomes | 2 | 2020 | 40 | 0.300 |
Why?
|
| Middle Aged | 7 | 2023 | 967 | 0.300 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 2018 | 19 | 0.250 |
Why?
|
| Endothelium, Vascular | 2 | 2023 | 17 | 0.250 |
Why?
|
| Interferon-gamma | 2 | 2018 | 7 | 0.240 |
Why?
|
| Acceleration | 1 | 2025 | 3 | 0.230 |
Why?
|
| Accelerometry | 1 | 2025 | 11 | 0.230 |
Why?
|
| Breast | 1 | 2025 | 15 | 0.230 |
Why?
|
| Interleukin-10 | 2 | 2017 | 8 | 0.230 |
Why?
|
| Time Factors | 3 | 2023 | 163 | 0.220 |
Why?
|
| Cells, Cultured | 2 | 2015 | 127 | 0.220 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2023 | 12 | 0.220 |
Why?
|
| Heart Rate | 3 | 2020 | 43 | 0.210 |
Why?
|
| Brachial Artery | 1 | 2023 | 2 | 0.210 |
Why?
|
| Vasodilation | 1 | 2023 | 7 | 0.210 |
Why?
|
| Peripheral Arterial Disease | 1 | 2023 | 4 | 0.210 |
Why?
|
| Inflammation Mediators | 1 | 2023 | 9 | 0.210 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2023 | 2 | 0.210 |
Why?
|
| Adolescent | 2 | 2020 | 758 | 0.210 |
Why?
|
| Nitric Oxide | 2 | 2020 | 11 | 0.200 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2023 | 4 | 0.200 |
Why?
|
| Melanoma | 1 | 2023 | 28 | 0.200 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 4 | 0.200 |
Why?
|
| Leukemia | 1 | 2023 | 6 | 0.200 |
Why?
|
| Fatigue | 1 | 2023 | 9 | 0.200 |
Why?
|
| Leukocytes | 1 | 2023 | 6 | 0.200 |
Why?
|
| Neoplasms | 2 | 2016 | 90 | 0.200 |
Why?
|
| Energy Metabolism | 1 | 2023 | 15 | 0.190 |
Why?
|
| Oxidative Stress | 2 | 2020 | 58 | 0.190 |
Why?
|
| Pilot Projects | 1 | 2023 | 98 | 0.190 |
Why?
|
| Resistance Training | 1 | 2022 | 5 | 0.190 |
Why?
|
| Affect | 1 | 2021 | 29 | 0.180 |
Why?
|
| Motor Activity | 2 | 2020 | 61 | 0.180 |
Why?
|
| Aging | 2 | 2013 | 109 | 0.170 |
Why?
|
| Leisure Activities | 1 | 2021 | 7 | 0.170 |
Why?
|
| Pandemics | 1 | 2021 | 73 | 0.170 |
Why?
|
| Wakefulness | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 3 | 0.170 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2020 | 5 | 0.170 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2020 | 5 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2020 | 16 | 0.170 |
Why?
|
| Viruses | 1 | 2020 | 11 | 0.160 |
Why?
|
| Physical Conditioning, Animal | 1 | 2020 | 29 | 0.160 |
Why?
|
| Cell Count | 2 | 2022 | 34 | 0.160 |
Why?
|
| Leukocyte Count | 2 | 2018 | 9 | 0.150 |
Why?
|
| Pleasure | 1 | 2018 | 3 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2018 | 11 | 0.140 |
Why?
|
| Arousal | 1 | 2018 | 6 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2018 | 8 | 0.140 |
Why?
|
| K562 Cells | 1 | 2018 | 10 | 0.140 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 17 | 0.140 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2016 | 21 | 0.140 |
Why?
|
| Coronary Vessels | 1 | 2018 | 27 | 0.140 |
Why?
|
| Photic Stimulation | 1 | 2018 | 136 | 0.140 |
Why?
|
| Motivation | 1 | 2018 | 69 | 0.140 |
Why?
|
| Child | 1 | 2020 | 627 | 0.130 |
Why?
|
| Aged | 4 | 2023 | 703 | 0.130 |
Why?
|
| Lymphocytosis | 1 | 2017 | 2 | 0.130 |
Why?
|
| Observational Studies as Topic | 1 | 2017 | 4 | 0.130 |
Why?
|
| Animals | 5 | 2023 | 1711 | 0.130 |
Why?
|
| Cellular Senescence | 2 | 2013 | 14 | 0.120 |
Why?
|
| Survivors | 1 | 2016 | 14 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2016 | 14 | 0.120 |
Why?
|
| Mice | 3 | 2023 | 685 | 0.120 |
Why?
|
| Dextrans | 1 | 2015 | 4 | 0.110 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2015 | 4 | 0.110 |
Why?
|
| Viral Matrix Proteins | 1 | 2015 | 4 | 0.110 |
Why?
|
| Immunophenotyping | 1 | 2015 | 8 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2015 | 16 | 0.110 |
Why?
|
| WT1 Proteins | 1 | 2015 | 3 | 0.110 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2015 | 3 | 0.110 |
Why?
|
| Hormones | 1 | 2015 | 4 | 0.110 |
Why?
|
| Transplantation, Autologous | 1 | 2015 | 6 | 0.110 |
Why?
|
| Antigen Presentation | 1 | 2015 | 6 | 0.110 |
Why?
|
| Cell Culture Techniques | 1 | 2015 | 24 | 0.110 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2015 | 14 | 0.110 |
Why?
|
| Exercise Test | 1 | 2015 | 41 | 0.110 |
Why?
|
| Serologic Tests | 1 | 2014 | 3 | 0.110 |
Why?
|
| CD4-CD8 Ratio | 1 | 2014 | 3 | 0.110 |
Why?
|
| CD3 Complex | 1 | 2014 | 5 | 0.110 |
Why?
|
| CD28 Antigens | 1 | 2014 | 5 | 0.110 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 6 | 0.110 |
Why?
|
| Receptors, Immunologic | 1 | 2014 | 9 | 0.110 |
Why?
|
| Trans-Activators | 1 | 2014 | 18 | 0.110 |
Why?
|
| Virus Diseases | 1 | 2013 | 2 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2013 | 6 | 0.100 |
Why?
|
| Immunity | 1 | 2013 | 8 | 0.100 |
Why?
|
| Case-Control Studies | 1 | 2013 | 81 | 0.100 |
Why?
|
| Interleukin-4 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2012 | 2 | 0.100 |
Why?
|
| Interleukin-2 | 1 | 2012 | 4 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2012 | 9 | 0.100 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 14 | 0.100 |
Why?
|
| Immunity, Cellular | 1 | 2012 | 4 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 3 | 0.090 |
Why?
|
| Phenotype | 2 | 2023 | 67 | 0.090 |
Why?
|
| Cross-Over Studies | 2 | 2022 | 31 | 0.080 |
Why?
|
| Diet, Fat-Restricted | 2 | 2020 | 4 | 0.080 |
Why?
|
| Catecholamines | 2 | 2020 | 8 | 0.080 |
Why?
|
| Diet, High-Fat | 2 | 2020 | 34 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 184 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2018 | 216 | 0.060 |
Why?
|
| Clothing | 1 | 2025 | 2 | 0.060 |
Why?
|
| Sports | 1 | 2025 | 7 | 0.060 |
Why?
|
| Movement | 1 | 2025 | 52 | 0.050 |
Why?
|
| Biomechanical Phenomena | 1 | 2025 | 154 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2023 | 18 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2023 | 27 | 0.050 |
Why?
|
| Phosphorylation | 1 | 2023 | 48 | 0.050 |
Why?
|
| Mice, Inbred Strains | 1 | 2023 | 6 | 0.050 |
Why?
|
| Age Factors | 2 | 2013 | 65 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2023 | 177 | 0.050 |
Why?
|
| Transcriptome | 1 | 2023 | 43 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2022 | 3 | 0.050 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 15 | 0.040 |
Why?
|
| Receptors, Adiponectin | 1 | 2020 | 2 | 0.040 |
Why?
|
| Zonula Occludens-2 Protein | 1 | 2020 | 2 | 0.040 |
Why?
|
| Adiponectin | 1 | 2020 | 3 | 0.040 |
Why?
|
| Superoxides | 1 | 2020 | 5 | 0.040 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2020 | 7 | 0.040 |
Why?
|
| Caspase 1 | 1 | 2020 | 11 | 0.040 |
Why?
|
| Interleukin-1beta | 1 | 2020 | 17 | 0.040 |
Why?
|
| Overweight | 1 | 2021 | 40 | 0.040 |
Why?
|
| Aorta | 1 | 2020 | 8 | 0.040 |
Why?
|
| Species Specificity | 1 | 2020 | 14 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 98 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 9 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2020 | 8 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2020 | 68 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2020 | 40 | 0.040 |
Why?
|
| Peptides | 1 | 2020 | 49 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2020 | 115 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 269 | 0.040 |
Why?
|
| Bisoprolol | 1 | 2018 | 9 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 32 | 0.040 |
Why?
|
| Nadolol | 1 | 2018 | 10 | 0.040 |
Why?
|
| Granulocytes | 1 | 2018 | 3 | 0.040 |
Why?
|
| Arterioles | 1 | 2018 | 4 | 0.040 |
Why?
|
| Mice, Obese | 1 | 2018 | 9 | 0.040 |
Why?
|
| United States | 1 | 2021 | 495 | 0.040 |
Why?
|
| Parvovirus B19, Human | 1 | 2013 | 2 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 3 | 0.030 |
Why?
|
| Simplexvirus | 1 | 2013 | 5 | 0.030 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 13 | 0.030 |
Why?
|
| Linear Models | 1 | 2013 | 58 | 0.030 |
Why?
|
| Prognosis | 1 | 2013 | 60 | 0.030 |
Why?
|